These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 22445760

  • 1. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.
    Zuleta A, Vidal RL, Armentano D, Parsons G, Hetz C.
    Biochem Biophys Res Commun; 2012 Apr 13; 420(3):558-63. PubMed ID: 22445760
    [Abstract] [Full Text] [Related]

  • 2. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy.
    Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, Caballero B, Kiffin R, Segura-Aguilar J, Cuervo AM, Glimcher LH, Hetz C.
    Hum Mol Genet; 2012 May 15; 21(10):2245-62. PubMed ID: 22337954
    [Abstract] [Full Text] [Related]

  • 3. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
    Ceccarelli I, Fiengo P, Remelli R, Miragliotta V, Rossini L, Biotti I, Cappelli A, Petricca L, La Rosa S, Caricasole A, Pollio G, Scali C.
    Neurobiol Dis; 2016 Feb 15; 86():41-51. PubMed ID: 26626080
    [Abstract] [Full Text] [Related]

  • 4. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
    Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D.
    Mol Ther; 2008 May 15; 16(5):947-56. PubMed ID: 18388917
    [Abstract] [Full Text] [Related]

  • 5. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B, Schiefer J, Sass C, Kosinski CM, Kochanek S.
    J Gene Med; 2008 Mar 15; 10(3):269-79. PubMed ID: 18067195
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
    Martin E, Betuing S, Pagès C, Cambon K, Auregan G, Deglon N, Roze E, Caboche J.
    Hum Mol Genet; 2011 Jun 15; 20(12):2422-34. PubMed ID: 21493629
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux.
    Lee H, Noh JY, Oh Y, Kim Y, Chang JW, Chung CW, Lee ST, Kim M, Ryu H, Jung YK.
    Hum Mol Genet; 2012 Jan 01; 21(1):101-14. PubMed ID: 21954231
    [Abstract] [Full Text] [Related]

  • 13. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
    Carty N, Berson N, Tillack K, Thiede C, Scholz D, Kottig K, Sedaghat Y, Gabrysiak C, Yohrling G, von der Kammer H, Ebneth A, Mack V, Munoz-Sanjuan I, Kwak S.
    PLoS One; 2015 Jan 01; 10(4):e0123527. PubMed ID: 25859666
    [Abstract] [Full Text] [Related]

  • 14. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
    Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, Déglon N.
    Neurobiol Dis; 2005 Dec 01; 20(3):785-98. PubMed ID: 16006135
    [Abstract] [Full Text] [Related]

  • 15. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X, Li G, Kaplan A, Gaschler MM, Zhang X, Hou Z, Jiang M, Zott R, Cremers S, Stockwell BR, Duan W.
    Hum Mol Genet; 2018 May 01; 27(9):1545-1555. PubMed ID: 29462355
    [Abstract] [Full Text] [Related]

  • 16. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, Schilling G, Crippen D, Wood JD, Sawa A, Jenkins NA, Copeland NG, Borchelt DR, Ross CA, Ellerby LM.
    Neurobiol Dis; 2006 Feb 01; 21(2):381-91. PubMed ID: 16150600
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
    Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D.
    Science; 2002 Jun 21; 296(5576):2238-43. PubMed ID: 11988536
    [Abstract] [Full Text] [Related]

  • 19. Expression of citrate carrier gene is activated by ER stress effectors XBP1 and ATF6α, binding to an UPRE in its promoter.
    Damiano F, Tocci R, Gnoni GV, Siculella L.
    Biochim Biophys Acta; 2015 Jan 21; 1849(1):23-31. PubMed ID: 25450523
    [Abstract] [Full Text] [Related]

  • 20. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
    Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, Rey M, Lubelski J, Evers MM, van Deventer SJ, Petry H, Déglon N, Konstantinova P.
    Gene Ther; 2017 Oct 21; 24(10):630-639. PubMed ID: 28771234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.